Cancer as the leading cause of death worldwide has many issues that still need to be addressed. Since the alterations on the glycan compositions or/and structures (i.e., glycosylation, sialylation, and fucosylation) are common features of tumorigenesis, glycomics becomes an emerging field examining the structure and function of glycans. In the past, cancer studies heavily relied on genomics and transcriptomics with relatively little exploration of the glycan alterations and glycoprotein biomarkers among individuals and populations. Since glycosylation of proteins increases their structural complexity by several orders of magnitude, glycome studies resulted in highly dynamic biomarkers that can be evaluated for cancer diagnosis, prognosis, and therapy. Glycome not only integrates our genetic background with past and present environmental factors but also offers a promise of more efficient patient stratification compared with genetic variations. Therefore, studying glycans holds great potential for better diagnostic markers as well as developing more efficient treatment strategies in human cancers. While recent developments in glycomics and associated technologies now offer new possibilities to achieve a high-throughput profiling of glycan diversity, we aim to give an overview of the current status of glycan research and the potential applications of the glycans in the scope of the personalized medicine strategies for cancer.
Get full access to this article
View all access options for this article.
References
1.
AbbottKL, and PierceJM. (2010). Lectin-based glycoproteomic techniques for the enrichment and identification of potential biomarkers. Methods Enzymol, 480, 461–476.
2.
AbdHamid, RoyleL, SaldovaR, et al. (2008). A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology, 18, 1105–1118.
3.
AdamczykB, TharmalingamT, and RuddPM. (2012). Glycans as cancer biomarkers. Biochim Biophys Acta, 1820, 1347–1353.
4.
AduaE, MemarianE, RussellA, et al. (2018). High throughput profiling of whole plasma N-glycans in type II diabetes mellitus patients and healthy individuals: A perspective from a Ghanaian population. Arch Biochem Biophys, 661, 10–21.
5.
AduaE, MemarianE, RussellA, Trbojević-AkmačićI, GudeljI, and WangW. (2019). Utilization of N-glycosylation profiles as risk stratification biomarkers for suboptimal health status and metabolic syndrome in a Ghanaian population. Biomark Med, 13, 1273–1287.
6.
AduaE, RussellA, RobertsP, WangY, SongM, and WangW. (2017). Innovation analysis on postgenomic biomarkers: Glycomics for chronic diseases. Omics, 21, 183–196.
7.
AggelisV, CravenRA, PengJ, et al. (2013). VHL-dependent regulation of a β-dystroglycan glycoform and glycogene expression in renal cancer. Int J Oncol, 43, 1368–1376.
8.
AhmedMB, AlmogbelE, KhirryI, HassanS, SalemT, and SaeedA. (2017). Diagnostic and prognostic significance of histidine-rich glycoprotein in acute lymphoblastic leukemia. Open J Blood Dis, 7, 16–28.
9.
AhnJM, SungHJ, YoonYH, et al. (2014). Integrated glycoproteomics demonstrates fucosylated serum paraoxonase 1 alterations in small cell lung cancer. Mol Cell Proteomics, 13, 30–48.
10.
AhnYH, ShinPM, OhNR, ParkGW, KimH, and YooJS. (2012). A lectin-coupled, targeted proteomic mass spectrometry (MRM MS) platform for identification of multiple liver cancer biomarkers in human plasma. J Proteomics, 75, 5507–5515.
11.
AlleyWR Jr, VasseurJA, GoetzJA, et al. (2012). N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. J Proteome Res, 11, 2282–2300.
12.
Alonso-RangelL, Benítez-GuerreroT, Martínez-VieyraI, et al. (2017). A role for dystroglycan in the pathophysiology of acute leukemic cells. Life Sci, 182, 1–9.
13.
Al-wajeehAS, IsmailMN, SalhimiSM, et al. (2007). Identification of glycobiomarker candidates for breast cancer using LTQ-Orbitrap fusion technique. Int J Pharmacol, 13, 425–437.
14.
AokiS, MotoiF, MurakamiY, et al. (2019). Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: A multicenter case-control study of 240 patients. BMC Cancer, 19, 252.
15.
ArnoldJN, SaldovaR, GalliganMC, et al. (2011). Novel glycan biomarkers for the detection of lung cancer. J Proteome Res, 10, 1755–1764.
16.
AsazawaH, KamadaY, TakedaY, et al. (2015). Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development. Clin Chem Lab Med, 53, 95–102.
17.
AtsumiS, MatsumineA, ToyodaH, NiimiR, IinoT, and SudoA. (2013). Prognostic significance of CD155 mRNA expression in soft tissue sarcomas. Oncol Lett, 5, 1771–1776.
18.
AutelitanoF, LoyauxD, and RoudieresS. (2014). Identification of novel tumor-associated cell surface sialoglycoproteins in human glioblastoma tumors using quantitative proteomics. PLoS One, 9:e110316.
19.
AyyubA, SaleemM, FatimaI, TariqA, HashmiN, and MusharrafSG. (2016). Glycosylated Alpha-1-acid glycoprotein 1 as a potential lung cancer serum biomarker. Int J Biochem Cell Biol, 70, 68–75.
20.
BabalP, JanegaP, CernaA, and KholovaI. (2006). Neoplastic transformation of the thyroid gland is accompanied by changes in cellular sialylation. Acta Histochem, 108, 133–140.
21.
BalmañaM, GiménezE, PuertaA, et al. (2016). Increased α1–3 fucosylation of α-1-acid glycoprotein (AGP) in pancreatic cancer. Proteomics, 132, 144–154.
22.
BalogCIA, StavenhagenK, FungWLJ, et al. (2012). N-glycosylation of colorectal cancer tissues: A liquid chromatography and mass spectrometry-based investigation. Mol Cell Proteomics, 11, 571–585.
23.
BarbareschiM, MaisonneuveP, AldoviniD, et al. (2003). High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer, 98, 474–483.
24.
BatlleM, RiberaJM, OriolA, et al. (2005). Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: Study of 200 patients. Leuk Lymphoma, 46, 1471–1476.
25.
BenickyJ, SandaM, PompachP, WuJ, and GoldmanR. (2014). Quantification of fucosylated hemopexin and complement factor H in plasma of patients with liver disease. Anal Chem, 86, 10716–10723.
26.
BiB, FangL, HanR, et al. (2017). Vimentin and PRG4 as candidate biomarkers of ovarian cancer using serum proteomic analysis of 2D-DIGE. Int J Clin Exp Med, 10, 4547–4555.
27.
BiskupK, BraicuEI, SehouliJ, TauberR, and BlanchardV. (2014). The serum glycome to discriminate between early-stage epithelial ovarian cancer and benign ovarian diseases. Dis Markers, 2014, 238197.
28.
BiskupK, BraicuEI, SehouliJ, TauberR, and BlanchardV. (2017). The ascites N-glycome of epithelial ovarian cancer patients. J Proteomics, 157, 33–39.
29.
BondarOP, BarnidgeDR, KleeEW, DavisBJ, and KleeGG. (2007). LC-MS/MS quantification of Zn-alpha2 glycoprotein: A potential serum biomarker for prostate cancer. Clin Chem, 53, 673–678.
30.
BonesJ, ByrneJC, O'DonoghueN, et al. (2011). Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms. J Proteome Res, 10, 1246–1265.
31.
Borzym-KluczykM, RadziejewskaI, and Cechowska-PaskoM. (2015). Increased expression of MUC1 and sialyl Lewis antigens in different areas of clear renal cell carcinoma. Clin Exp Nephrol, 19, 732–737.
32.
BoysenG, Bausch-FluckD, ThomaCR, et al. (2012). Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma. Neoplasia, 14, 535–546.
33.
BresalierRS, YanP, ByrdJC, LotanR, and RazA. (1997). Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer Interdiscip Int J Am Cancer Soc, 80, 776–787.
34.
BuettnerMJ, ShahSR, SaeuiCT, ArissR, and YaremaKJ. (2018). Improving immunotherapy through glycodesign. Front immunol, 9, 2485.
35.
CagnoniAJ, Perez SaezJM, RabinovichGA, and MariñoKV. (2016). Turning-off signaling by siglecs, selectins, and galectins: Chemical inhibition of glycan-dependent interactions in cancer. Front Oncol, 6, 109.
36.
CamposD, FreitasD, GomesJ, et al. (2015). Probing the O-glycoproteome of gastric cancer cell lines for biomarker discovery. Mol Cell Proteomics, 14, 1616–1629.
37.
CarvalhoS, CatarinoTA, and DiasAM. (2016). Preventing E-cadherin aberrant N-glycosylation at Asn-554 improves its critical function in gastric cancer. Oncogene, 35, 1619–1631.
38.
ChangSC, LinWL2, ChangYF, et al. (2019). Glycoproteomic identification of novel plasma biomarkers for oral cancer. J Food Drug Anal, 27, 483–493.
39.
ChauhanSC, SinghAP, RuizF, et al. (2006). Aberrant expression of MUC4 in ovarian carcinoma: Diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod Pathol, 19, 1386–1394.
40.
ChenF, IshikawaY, AkashiA, NaoeT, and KiyoiH. (2016). Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells. Oncotarget, 7, 47018–47032.
41.
ChenH, DengZ, HuangC, WuH, ZhaoX, and LiY. (2017). Mass spectrometric profiling reveals association of N-glycan patterns with epithelial ovarian cancer progression. Tumour Biol, 39: 1010428317716249.
42.
ChenJT, ChenCH, KuKL, et al. (2015). Glycoprotein B7-H3 overexpression and aberrant glycosylation in oral cancer and immune response. Proc Natl Acad Sci U S A, 112, 13057–13062.
43.
ChenYT1, ChongYM, ChengCW, et al. (2013). Identification of novel tumor markers for oral squamous cell carcinoma using glycoproteomic analysis. Clin Chim Acta, 420, 45–53.
44.
ChesnokovaV, ZonisS, and ZhouC. (2011). Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PLoS One, 6, e17924.
45.
ComunaleMA, LowmanM, LongRE, et al. (2006). Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res, 5, 308–315.
46.
ComunaleMA, Rodemich-BeteshL, HafnerJ, et al. (2010). Linkage specific fucosylation of alpha-1-antitrypsin in liver cirrhosis and cancer patients: Implications for a biomarker of hepatocellular carcinoma. PLoS One, 5, e12419.
47.
ComunaleMA, WangM, HafnerJ, et al. (2009). Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. J Proteome Res, 8, 595–602.
48.
ComunaleMA, WangM, Rodemich-BeteshL, et al. (2011) Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev, 20, 1222–1229.
49.
ConklinMW, EickhoffJC, RichingKM, et al. (2011). Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am J Pathol, 178, 1221–1232.
50.
CorreiaM, ThiagarajanV, CoutinhoI, GajulaGP, PetersenSB, and Neves-PetersenMT. (2014). Modulating the structure of EGFR with UV light: New possibilities in cancer therapy. PLoS One, 9, e111617.
51.
CostaJ, GatermannM, NimtzM, KandziaS, GlatzelM, and ConradtHS. (2018). N-glycosylation of extracellular vesicles from HEK-293 and glioma cell lines. Anal Chem, 90, 7871–7879.
52.
CottonS, AzevedoR, GaiteiroC, et al. (2017). Targeted O-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced-stage bladder tumours. Mol Oncol, 11, 895–912.
53.
DalzielM, CrispinM, ScanlanCN, ZitzmannN, and DwekRA. (2014). Emerging principles for the therapeutic exploitation of glycosylation. Science, 343, 1235681.
54.
DasA, TanWL, and SmithDR. (2003). Expression of extracellular matrix markers in benign meningiomas. Neuropathology, 23, 275–281.
55.
DavisAP, MurphyCG, Saraceni-RichardsCA, RosensteinMC, WiegersTC, and MattinglyCJ. (2009). Comparative Toxicogenomics Database: A knowledgebase and discovery tool for chemical–gene–disease networks. Nucleic Acids Res, 37, D786–D792.
56.
de LeozML, YoungLJ, AnHJ, et al. (2011). High-mannose glycans are elevated during breast cancer progression. Mol Cell Proteomics 10, M110.002717.
57.
DědováT, BraicuEI, SehouliJ, and BlanchardV. (2019). Sialic acid linkage analysis refines the diagnosis of ovarian cancer. Front Oncol, 9, 261.
58.
DickerM, and StrasserR. (2015). Using glyco-engineering to produce therapeutic proteins. Expert Opin Biol Ther, 15, 1501–1516.
59.
DilekI, AyaktaH, DemirC, MeralC, and OzturkM. (2005). CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies. Clin Lab Haematol, 27, 51–55.
60.
DingQ, ZhangM, and LiuC. (2015). Asporin participates in gastric cancer cell growth and migration by influencing EGF receptor signaling. Oncol Rep, 33, 1783–1790.
61.
DohertyM, TheodoratouE, WalshI, et al. (2018). Plasma N-glycans in colorectal cancer risk. Sci rep, 8, 1–12.
62.
DorfmanDM, and ShahsafaeiA. (2011). CD200 (OX-2 membrane glycoprotein) is expressed by follicular T helper cells and in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol, 35, 76–83.
63.
DrakeRR, JonesEE, PowersTW, and NyalwidheJO. (2015). Altered glycosylation in prostate cancer. Adv Cancer Res, 126, 345–382.
64.
DuffyMJ. (1999). CA 15-3 and relatedmucins as circulating markers in breast cancer. Ann Clin Biochem, 36, 579–586.
65.
DürigJ, NascharM, SchmückerU, et al. (2002). CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia, 16, 30–35.
66.
DvorakHF. (2015) Tumors: Wounds that do not heal—redux. Cancer Immunol Res 3, 1–1.
67.
EdwardsAM, IsserlinR, BaderGD, FryeSV, WillsonTM, and FrankHY. (2011). Too many roads not taken. Nature, 470, 163–165.
68.
EistererW, BechterO, SöderbergO, et al. (2004). Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia. Leuk Res, 28, 1043–1051.
69.
EliasD, and DitzelHJ. (2015). Fyn is an important molecule in cancer pathogenesis and drug resistance. Pharmacol Res, 100, 250–254.
70.
Everest-DassAV, BriggsMT, KaurG, OehlerMK, HoffmannP, and PackerNH. (2016). N-glycan MALDI imaging mass spectrometry on formalin-fixed paraffin-embedded tissue enables the delineation of ovarian cancer tissues. Mol Cell Proteomics, 15, 3003–3016.
71.
FabregatA, JupeS, MatthewsL, SidiropoulosK, et al. (2018) The reactome pathway knowledgebase. Nucleic Acids Res 46(D1), D649–D655.
72.
FangC, CaoY, LiuX, ZengXT, and LiY. (2017). Serum CA125 is a predictive marker for breast cancer outcomes and correlates with molecular subtypes. Oncotarget, 8, 63963–63970.
73.
FentonM, WhitesideTL, FerroneS, and BoyiadzisM. (2015). Chondroitin sulfate proteoglycan-4 (CSPG4)-specific monoclonal antibody 225.28 in detection of acute myeloid leukemia blasts. Oncol Res, 22, 117–121.
74.
FerreiraJA, VideiraPA, LimaL, et al. (2013). Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours. Mol Oncol, 7, 719–731.
75.
GaoY, MaF, ZhangW, et al. (2013). O-glycan profiling of serum glycan for potential renal cancer biomarkers. Sci China Life Sci, 56, 739–744.
76.
GbormittahFO, BonesJ, HincapieM, TousiF, HancockWS, and IliopoulosO. (2015). Clusterin glycopeptide variant characterization reveals significant site-specific glycan changes in the plasma of clear cell renal cell carcinoma. J Proteome Res, 14, 2425–2436.
77.
GeS, WangY, SongM, et al. (2018). Type 2 diabetes mellitus: Integrative analysis of multiomics data for biomarker discovery. OMICS, 22, 514–523.
78.
GebrehiwotAG, MelkaDS, KassayeYM, et al. (2019). Exploring serum and immunoglobulin G N-glycome as diagnostic biomarkers for early detection of breast cancer in Ethiopian women. BMC Cancer, 19, 588.
79.
GhoshR, GildaJE, and GomesAV. (2014). The necessity of and strategies for improving confidence in the accuracy of western blots. Expert Rev, Proteomics11, 549–560.
80.
GhoshS, BandyopadhyayS, PalS, DasB, BhattacharyaDK, and MandalC. (2005). Increased interferon gamma production by peripheral blood mononuclear cells in response to stimulation of overexpressed disease-specific 9-O-acetylated sialoglycoconjugates in children suffering from acute lymphoblastic leukaemia. Br J Haematol, 128, 35–41.
81.
GionM, MioneR, LeonAE, et al. (2001). CA27.29: A valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer, 37, 355–363.
82.
GreerDA, and IveyS. (2007). Distinct N-glycan glycosylation of P-glycoprotein isolated from the human uterine sarcoma cell line MES-SA/Dx5. Biochim Biophys Acta, 1770, 1275–1282.
83.
GressnerAM, GaoCF, and GressnerOA. (2009). Non-invasive biomarkers for monitoring the fibrogenic process in liver: A short survey. World J Gastroenterol, 15, 2433.
84.
GrünewaldS, MatthijsG, and JaekenJ. (2002). Congenital disorders of glycosylation: A review. Pediatr Res, 52, 618–624.
85.
GündüzUR, GunaldiM, IsiksacanN, GündüzS, OkuturlarY, and KocogluH. (2016). A new marker for breast cancer diagnosis, human epididymis protein 4: A preliminary study. Mol Clin Oncol, 5, 355–360.
86.
GuuSY, LinTH, ChangSC, et al. (2017). Serum N-glycome characterization and anti-carbohydrate antibody profiling in oral squamous cell carcinoma patients. PLoS One, 12, e0178927.
87.
HaabBB. (2012). Using lectins in biomarker research: Addressing the limitations of sensitivity and availability. Proteomics Clin Appl, 6, 346–350.
88.
HariprasadG, HariprasadR, KumarL, SrinivasanA, KolaS, and KaushikA. (2013). Apolipoprotein A1 as a potential biomarker in the ascitic fluid for the differentiation of advanced ovarian cancers. Biomarkers, 18, 532–541.
89.
HatekayemaS, AmanoM, TobisawaY, et al. (2014). Serum N-Glycan alteration associated with renal cell carcinoma detected by high throughput glycan analysis. Invest Urol, 191, 805–813.
90.
HäuselmannI, and BorsigL. (2014). Altered tumor-cell glycosylation promotes metastasis. Front Oncol, 4, 28.
91.
HeJ, LiuY, and ZhuTS. (2011). Glycoproteomic analysis of glioblastoma stem cell differentiation. J Proteome Res, 10, 330–338.
92.
HeawchaiyaphumC, PientongC, PhusinghaP, et al. (2018). Peroxiredoxin-2 and zinc-alpha-2-glycoprotein as potentially combined novel salivary biomarkers for early detection of oral squamous cell carcinoma using proteomic approaches. J Proteomics, 173, 52–61.
93.
HeoSH, LeeSJ, RyooHM, ParkJY, and ChoJY. (2007). Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS. Proteomics, 7, 4292–4302.
94.
HishinumaM, OhashiKI, YamauchiN, et al. (2006). Hepatocellular oncofetal protein, glypican 3 is a sensitive marker for alpha-fetoprotein-producing gastric carcinoma. Histopathology, 49, 479–486.
95.
HoaglandLF 4th, CampaMJ, GottlinEB, HerndonJE 2nd, and PatzEF Jr. (2007) Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. Cancer 110, 2260–2268.
96.
HongsachartP, Huang-LiuR, SinchaikulS, et al. (2009). Glycoproteomic analysis of WGA-bound glycoprotein biomarkers in sera from patients with lung adenocarcinoma. Electrophoresis, 30, 1206–1220.
97.
HsuSC, NadesanP, PuviindranV, StallcupWB, KirschDG, and AlmanBA. (2018). Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage. J Biol Chem, 293, 2466–2475.
98.
HuaS, WilliamsCC, DimapasocLM, et al. (2013). Isomer-specific chromatographic profiling yields highly sensitive and specific potential N-glycan biomarkers for epithelial ovarian cancer. J Chromatogr A 1, 1279, 58–67.
99.
HuangCY, ChengWF, LeeCN, et al. (2006). Serum mesothelin in epithelial ovarian carcinoma: A new screening marker and prognostic factor. Anticancer Res, 26, 4721–4728.
100.
HussainiIM, TrotterC, ZhaoY, et al. (2007). Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. Am J Pathol, 170, 356–365.
101.
HwangH, JeongHK, LeeHK, et al. (2020). Machine learning classifies core and outer fucosylation of N-glycoproteins using mass spectrometry. Sci Rep, 10, 318.
102.
JaskiewiczNM, HermawanC, ParisiS, and TownsonDH. (2017). O-GlcNAcylation enhances the tumorigenic properties of cervical cancer cells in vitro. Clin Obstet Gynecol Reprod Med, 3, 1–6.
103.
JefferisR. (2009). Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov, 8, 226–234.
104.
JinY, KimSC, KimHJ, JuW, KimYH, and KimHJ. (2016). Increased sialylation and reduced fucosylation of exfoliated cervical cells are potential markers of carcinogenesis in the cervix. Clin Chem Lab Med, 54, 1811–1819.
105.
JohnsonMD, VitoF, and O'ConnellMJ. (2008). Mesothelin expression in the leptomeninges and meningiomas. J Histochem Cytochem, 56, 579–585.
106.
JuL, WangY, XieQ, et al. (2016). Elevated level of serum glycoprotein bifucosylation and prognostic value in Chinese breast cancer. Glycobiology, 26, 460–471.
107.
JulienS, IveticA, GrigoriadisA, et al. (2011). Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers. Cancer Res, 71, 7683–7693.
108.
KajiH, OchoM, TogayachiA, et al. (2013). Glycoproteomic discovery of serological biomarker candidates for HCV/HBV infection-associated liver fibrosis and hepatocellular carcinoma. J Proteome Res, 12, 2630–2640.
109.
KanehisaM, ArakiM, GotoS, et al. (2007). KEGG for linking genomes to life and the environment. Nucleic Acids Res, 36, D480–D484.
110.
KaragozK, SevimogluT, and ArgaKY. (2016). Integration of multiple biological features yields high confidence human protein interactome. J TheorBiol, 403, 85–96.
111.
KatafigiotisI, TyritzisSI, StravodimosKG, et al. (2012). Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer. BJU Int, 110, E688–E693.
112.
KazanskayaGM, TsidulkoAY, VolkovAM, et al. (2018). Heparan sulfate accumulation and perlecan/HSPG2 up-regulation in tumour tissue predict low relapse-free survival for patients with glioblastoma. Histochem Cell Biol, 149, 235–244.
113.
KhanNI, CisterneA, DevidasM, et al. (2008). Expression of CD44, but not CD44v6, predicts relapse in children with B cell progenitor acute lymphoblastic leukemia lacking adverse or favorable genetics. Leuk Lymphoma, 49, 710–718.
114.
KimHJ, KimSC, JuW, KimYH, YinSY, and KimHJ. (2014). Aberrant sialylation and fucosylation of intracellular proteins in cervical tissue are critical markers of cervical carcinogenesis. Oncol Rep, 31, 1417–1422.
115.
KimJW, ParkY, RohJL, et al. (2016). Prognostic value of glucosylceramide synthase and P-glycoprotein expression in oral cavity cancer. Int J Clin Oncol, 21, 883–889.
116.
KimYI, LeeA, LeeBH, and KimSY. (2011). Prognostic significance of syndecan-1 expression in cervical cancers. J Gynecol Oncol, 2, 161–167.
117.
KobayashiK, MatsumotoH, MatsuyamaH, et al. (2016). Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer. Oncol Rep, 36, 2852–2860.
118.
KodamaJ, Hasengaowa, KusumotoT, et al. (2007). Versican expression in human cervical cancer. Eur J Cancer, 43, 1460–1466.
119.
KohliM, ShivamAK, AhujaP, and DuttaJ. (2019). Mucin-4: A novel marker for oral cancer. J Oral Maxillofac Pathol, 23, 49–53.
120.
KreuninP, ZhaoJ, RosserC, UrquidiV, LubmanDM, and GoodisonS. (2007). Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J Proteome Res, 6, 2631–2639.
121.
KrysovS, PotterKN, MockridgeCI, et al. (2010). Surface IgM of CLL cells displays unusual glycans indicative of engagement of antigen in vivo. Blood, 115, 4198–4205.
122.
KunejT. (2019). Rise of systems glycobiology and personalized glycomedicine: Why and how to integrate glycomics with multiomicsscience?.OMICS 23, 615–622.
123.
KusumotoT, KodamaJ, SekiN, NakamuraK, HongoA, and HiramatsuY. (2010). Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer. Oncol Rep, 23, 917–925.
124.
KyselovaZ, MechrefY, KangP, et al. (2008). Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Clin Chem, 54, 1166–1175.
125.
LaiHY, FengCQ, ZhangZY, TangH, ChenW, and LinH. (2018). A brief survey of machine learning application in cancer lectin identification. Curr Gene Ther, 18, 257–267.
126.
LarsenHØ, RougAS, JustT, BrownGD, and HoklandP. (2012). Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up. Cytometry B Clin Cytom, 82, 3–8.
127.
LaucG, HuffmanJE, PučićM, et al. (2013) Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet 9, e1003225.
128.
LawrenceMS, StojanovP, MermelCH, et al. (2014). Discovery and saturation analysis of cancer genes across 21 tumour types. Nature, 505, 495–501.
129.
LeungF, BernardiniMQ, BrownMD, et al. (2016). Validation of a novel biomarker panel for the detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev, 25, 1333–1340.
130.
LeungF, DimitromanolakisA, KobayashiH, DiamandisEP, and KulasingamV. (2013). Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients. Clin Biochem, 46, 1462–1468.
131.
LiG, LiM, LiangX, et al. (2017). Identifying DCN and HSPD1 as Potential Biomarkers in Colon Cancer Using 2D-LC-MS/MS Combined with iTRAQ Technology. J Cancer, 8, 479–489.
132.
LiXP, ZhangXW, ZhengLZ, and GuoWJ. (2015). Expression of CD44 in pancreatic cancer and its significance. Int J Clin Exp Pathol, 8, 6724–6731.
133.
LiY, WenT, ZhuM, et al. (2013). Glycoproteomic analysis of tissues from patients with colon cancer using lectin microarrays and nanoLC-MS/MS. Mol Biosyst, 9, 1877.
134.
LiangY, HanP, WangT, et al. (2019). Stage-associated differences in the serum N- and O-glycan profiles of patients with non-small cell lung cancer. Clin Proteomics, 16, 20.
135.
LiangY, MaT, ThakurA, et al. (2015). Differentially expressed glycosylated patterns of α-1-antitrypsin as serum biomarkers for the diagnosis of lung cancer. Glycobiology, 25, 331–340.
136.
LimaL, SeverinoPF, SilvaM, et al. (2013). Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy. Br J Cancer, 109, 2106–2114.
137.
LindénM, SegerstenU, RunesonM, et al. (2013). Tumour expression of bladder cancer-associated urinary proteins. BJU Int, 112, 407–415.
138.
LiuB, MaX, LiuQ, XiaoY, PanS, and JiaL. (2018a). Aberrant mannosylation profile and FTX/miR-342/ALG3-axis contribute to development of drug resistance in acute myeloid leukemia. Cell Death Dis, 9, 688.
139.
LiuJ, HanH, FanZ, et al. (2018b). AZGP1 inhibits soft tissue sarcoma cells invasion and migration. BMC Cancer, 18, 89.
140.
LiuD, ChuX, WangH, et al. (2018c). The changes of immunoglobulin G N-glycosylation in blood lipids and dyslipidaemia. J Transl Med, 16, 235.
141.
LiuX, NieH, ZhangY, et al. (2013). Cell surface-specific N-glycan profiling in breast cancer. PLoS One, 8, e72704.
142.
LiuY, HeJ, LiC, et al. (2010). Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations. J Proteome Res, 9, 798–805.
143.
LuJP, KneževićA, WangYX, et al. (2011). Screening novel biomarkers for metabolic syndrome by profiling human plasma N-glycans in Chinese Han and Croatian populations. J Proteome Res, 10, 4959–4969.
144.
LuP, WeaverVM, and WerbZ. (2012). The extracellular matrix: A dynamic niche in cancer progression. J Cell Biol, 196, 395–406.
145.
LusisEA, ChicoineMR, and PerryA. (2005). High throughput screening of meningioma biomarkers using a tissue microarray. J Neurooncol, 73, 219–223.
146.
MaH, ZhouH, SongX, ShiS, ZhangJ, and JiaL. (2015). Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia. Oncogene, 34, 726–740.
147.
MacCarthy-MorroghL, and MartinP. (2020). The hallmarks of cancer are also the hallmarks of wound healing. Sci Signal, 13, eaay8690.
148.
MachadoE1, KandziaS, CarilhoR, AltevogtP, ConradtHS, and CostaJ. (2011). N-Glycosylation of total cellular glycoproteins from the human ovarian carcinoma SKOV3 cell line and of recombinantly expressed human erythropoietin. Glycobiology, 21, 376–386.
149.
Maines-BandieraS, WooMM, BorugianM, et al. (2010). Oviductal glycoprotein (OVGP1, MUC9): A differentiation-based mucin present in serum of women with ovarian cancer. Int J Gynecol Cancer, 20, 16–22.
150.
ManimalaJC, RoachTA, LiZ, and GildersleeveJC. (2006). High-throughput carbohydrate microarray analysis of 24 lectins. Angew Chem Int Ed Engl, 45, 3607–3610.
151.
MannB, KlussmannE, and Vandamme-FeldhausV. (1997). Low O-acetylation of sialyl-Le(x) contributes to its overexpression in colon carcinoma metastases. Int J Cancer, 72, 258–264.
152.
MargelD, TalR, and BanielJ. (2007). Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer. J Urol, 178, 2297–2301.
153.
MarjonKD, TerminiCM, KarlenKL, et al. (2016). Tetraspanin CD82 regulates bone marrow homing of acute myeloid leukemia by modulating the molecular organization of N-cadherin. Oncogene, 35, 4132–4140.
154.
MarrelliD, PintoE, De StefanoA, et al. (2001). Preoperative positivity of serum tumor markers is a strong predictor of hematogenous recurrence of gastric cancer. J Surg Oncol, 78, 253–258.
155.
MartinerieC, GicquelC, LouvelA, LaurentM, SchofieldPN, and Le BoucY. (2001). Altered expression of novH is associated with human adrenocortical tumorigenesis. J Clin Endocrinol Metab, 86, 3929–3940.
156.
MatsumineA, ShintaniK, KusuzakiK, et al. (2007). Expression of decorin, a small leucine-rich proteoglycan, as a prognostic factor in soft tissue tumors. J Surg Oncol, 96, 411–418.
157.
MeanyDL, ZhangZ, SokollLJ, ZhangH, and ChanDW. (2009). Glycoproteomics for prostate cancer detection: Changes in serum PSA glycosylationpatterns. J Proteome Res, 8, 613–619.
158.
MereiterS, MagalhãesA, AdamczykB, et al. (2016). Glycomic analysis of gastric carcinoma cells discloses glycans as modulators of RON receptor tyrosine kinase activation in cancer. Biochim Biophys Acta, 1860, 1795–1808.
159.
MiaoY, ZongM, JiangT, et al. (2016). A comparative analysis of ESM-1 and vascular endothelial cell marker (CD34/CD105) expression on pituitary adenoma invasion. Pituitary, 19, 194–201.
160.
MontgomeryMR, and HullEE. (2019). Alterations in the glycome after HDAC inhibition impact oncogenic potential in epigenetically plastic SW13 cells. BMC Cancer, 19, 79.
161.
MoradSA, TanSF, FeithDJ, et al. (2015). Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia—Impact on enzyme activity and response to cytotoxics. Biochim Biophys Acta, 1851, 919–928.
162.
NakadaM, MiyamoriH, KitaD, et al. (2005). Human glioblastomas overexpress ADAMTS-5 that degrades brevican. Acta Neuropathol, 110, 239–246.
163.
NakataD. (2014). Increased N-glycosylation of Asn88 in serum pancreatic ribonuclease 1 is a novel diagnostic marker for pancreatic cancer. Sci Rep, 4, 6715.
164.
NarayanasamyA, AhnJM, SungHJ, et al. (2011). Fucosylated glycoproteomic approach to identify a complement component 9 associated with squamous cell lung cancer (SQLC). J Proteome, 74, 2948–2958.
165.
NieH, LiuX, ZhangY, et al. (2015). Specific N-glycans of Hepatocellular Carcinoma Cell Surface and the Abnormal Increase of Core-α-1, 6-fucosylated Triantennary Glycan via N-acetylglucosaminyltransferases-IVa Regulation. Sci Rep, 5, 16007.
166.
NiemannCU, KjeldsenL, RalfkiaerE, JensenMK, and BorregaardN. (2007). Serglycin proteoglycan in hematologic malignancies: A marker of acute myeloid leukemia. Leukemia, 21, 2406–2410.
167.
OhtsuboK, and MarthJD. (2006) Glycosylation in cellular mechanisms of health and disease. Cell 126, 855–867.
168.
OlfatGS, YasserHN, MoatazMK, ZiadSG, and AhmedME. (2014). Chitinase-3-Like Protein1 (YKL-40) as biomarker in serum of egyptian breast cancer females. Biochem Anal Biochem, 3, 149.
169.
ÖzdemirV, ArgaKY, AzizRK, et al. (2020). Digging deeper into precision/personalized medicine: cracking the sugar code, the third alphabet of life, and sociomateriality of the cell. OMICS, 24, 62–80.
170.
ÖzdemirV. (2020). Why are some omics biotechnologies more popular than others? the sociomateriality of glycans offers new clues. OMICS, 24, 57–59.
171.
PalA, HalitiP, DharmadhikariB, QiW, and PatraP. (2020). Manipulating extracellular matrix organizations and parameters to control local cancer invasion. IEEE/ACM Trans Comput Biol Bioinform, 1, 1.
172.
PanS, ChenR, TamuraY, et al. (2014). Quantitative glycoproteomics analysis reveals changes in N-glycosylation level associated with pancreatic ductal adenocarcinoma. J Proteome Res, 13, 1293–1306.
173.
ParkSY, LeeSH, KawasakiN, et al. (2011). α1–3/4 fucosylation at Asn 241 of β-haptoglobin is a novel marker for colon cancer: A combinatorial approach for development of glycan biomarkers. Int J Cancer, 130, 2366–2376.
174.
PavlikovaL, SeresM, ImrichovaD, et al. (2016). The expression of P-gp in leukemia cells is associated with cross-resistance to protein N-glycosylation inhibitor tunicamycin. Gen Physiol Biophys, 35, 497–510.
175.
PellegattaS, SavoldoB, Di IanniN, et al. (2018). Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy. Sci Transl Med, 10, eaao2731.
176.
PengC, YangY, JiL, YangP, YangX, and ZhangY. (2020). Cyclin H predicts the poor prognosis and promotes the proliferation of ovarian cancer. Cancer Cell Int, 20:316.
177.
PeredaMP, LeddaMF, GoldbergV, et al. (2000). High levels of matrix metalloproteinases regulate proliferation and hormone secretion in pituitary cells. J Clin Endocrinol Metab, 85, 263–269.
178.
PetroviciK, GrafM, HechtK, ReifS, PfisterK, and SchmetzerH. (2010). Use of NG2 (7.1) in AML as a tumor marker and its association with a poor prognosis. Cancer Genomics Proteomics, 7, 173–180.
179.
PierceA, SaldovaR, Abd HamidUM, et al. (2010). Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patients. Glycobiology, 20, 1283–1288.
180.
PirincciN, GecitI, GunesM, et al. (2012). Haptoglobin levels in Turkish patients with bladder cancer and its association with clinicopathological features. Asian Pac J Cancer Prev, 13, 6063–6066.
181.
QianJY, TanYL, ZhangY, YangYF, and LiXQ. (2018). Prognostic value of glypican-1 for patients with advanced pancreatic cancer following regional intra-arterial chemotherapy. Oncol Lett, 16, 1253–1258.
182.
QinR, ZhaoJ, QinW, ZhangZ, ZhaoR, and HanJ. (2017). Discovery of non-invasive glycan biomarkers for detection and surveillance of gastric cancer. J Cancer, 8, 1908.
183.
RadcliffeCM, ArnoldJN, SuterDM, et al. (2007). Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J Biol Chem, 282, 7405–7415.
184.
RenAH, FialaCA, DiamandisEP, and KulasingamV. (2020). Pitfalls in cancer biomarker discovery and validation with emphasis on circulating tumor DNA. Cancer Epidemiol Biomarkers Prev, 29, 12.
185.
RhoJH, LaddJJ, LiCI, et al. (2018). Protein and glycomic plasma markers for early detection of adenoma and colon cancer. Gut, 67, 473–484.
186.
RodriguezE, SchettersST, and van KooykY. (2018). The tumour glyco-code as a novel immune checkpoint for immunotherapy. Nat Rev Immunol, 18, 204–211.
187.
RuhaakLR, BarkauskasDA, and TorresJ. (2015a). The serum immunoglobulin G glycosylation signature of gastric cancer. EuPA Open Proteomics, 6, 1–9.
188.
RuhaakLR, TaylorSL, StrobleC, et al. (2015b). Differential N-glycosylation patterns in lung adenocarcinoma tissue. J Proteome Res, 14, 4538–4549.
189.
RussellAC, ŠimurinaM, GarciaMT, et al. (2017). The N-glycosylation of immunoglobulin G as a novel biomarker of Parkinson's disease. Glycobiology, 27, 501–510.
190.
SadéeW, and DaiZ. (2005). Pharmacogenetics/genomics and personalized medicine.Hum Mol Genet 14 Spec No. 2, R207–R214.
191.
SaitoYD, JensenAR, SalgiaR, EdwinM, and PosadasEM. (2010). Fyn: A novel molecular target in prostate cancer. Cancer, 116, 1629–1637.
192.
SaldovaR, WormaldMR, DwekRA, and RuddPM. (2008). Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis. Dis Markers, 25, 219–232.
193.
SaldovaR, ReubenJM, Abd HamidUM, RuddPM, and CristofanilliM. (2011). Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts. Ann Oncol, 22, 1113–1119.
194.
SchiopuC, Vukelić Ž, CapitanF, Kalanj-BognarS, SisuE, and ZamfirAD. (2012). Chip-nanoelectrospray quadrupole time-of-flight tandem mass spectrometry of meningioma gangliosides: A preliminary study. Electrophoresis, 33, 1778–1786.
195.
SchjoldagerKT, NarimatsuY, JoshiHJ, and ClausenH. (2020). Global view of human protein glycosylation pathways and functions. Nat Rev Mol Cell Biol, 21, 1–21.
196.
SchmidtM, MockA, JungkC, et al. (2016). Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade. Oncotarget, 7, 14551–14568.
197.
SchultenHJ, and HusseinD. (2019). Array expression meta-analysis of cancer stem cell genes identifies upregulation of PODXL especially in DCC low expression meningiomas. PLoS One, 14, e0215452.
198.
ScottDA, CasadonteR, CardinaliB, et al. (2019). Increases in tumor N-Glycan polylactosamines associated with advanced HER2-positive and triple-negative breast cancer tissues. Proteomics Clin Appl, 13, e1800014.
199.
SebastianA, AlzainMA, AswetoCO, et al. (2016). Glycan biomarkers for rheumatoid arthritis and its remission status in Han Chinese Patients. OMICS, 20, 343–351.
200.
SethiMK, HancockWS, and FanayanS. (2016). Identifying N-glycan biomarkers in colorectal cancer by mass spectrometry. Acc Chem Res, 49, 2099–2106.
201.
ShahM, TelangS, RavalG, ShahP, and PatelPS. (2008). Serum fucosylation changes in oral cancer and oral precancerous conditions: Alpha-L-fucosidase as a marker. Cancer, 113, 336–346.
202.
ShannonP, MarkielA, OzierO, et al. (2003). Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res, 13, 2498–2504.
203.
ShaoY, YuY, HeY, ChenQ, and LiuH. (2019). Serum ATX as a novel biomarker for breast cancer. Medicine (Baltimore), 98, e14973.
204.
ShinozakiE, TanabeK, AkiyoshiT, et al. (2018). Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: A novel colorectal cancer marker. BMC Cancer, 18, 406.
205.
ShuH, ZhangS, KangX, et al. (2011).Protein expression and fucosylated glycans of the serum haptoglobin-{beta} subunit in hepatitis B virus-based liver diseases. Acta Biochim Biophys Sin (Shanghai) 43, 528–534.
206.
SilvestriI, TestaF, and ZappasodiR. (2014). Sialidase NEU4 is involved in glioblastoma stem cell survival. Cell Death Dis, 5, 1381.
207.
SineviciN, MittermayrS, DaveyGP, BonesJ, and O'SullivanJ. (2019). Salivary N-glycosylation as a biomarker of oral cancer: A pilot study. Glycobiology, 29, 726–734.
208.
SmithKD, BehanJ, Matthews-SmithG, and MaglioccoAM. (2012). Alpha-1-Acid glycoprotein (AGP) as a potential biomarker for breast cancer. In: Glycosylation. Intech Open, Rijeke,Croatia.
209.
SongJY, LeeJK, LeeNW, YeomBW, KimSH, and LeeKW. (2009).Osteopontin expression correlates with invasiveness in cervical cancer. Aust N Z J Obstet Gynaecol 49, 434–438.
210.
StelzerG, RosenR, PlaschkesI, et al. (2016). The GeneCards Suite: From gene data mining to disease genome sequence analysis. Curr Protoc Bioinformatics 54:1.30.1–1.30.33.
211.
SunC, ChenP, ChenQ, et al. (2012). Serum paraoxonase 1 heteroplasmon, a fucosylated, and sialylated glycoprotein in distinguishing early hepatocellular carcinoma from liver cirrhosis patients. Acta Biochim Biophys Sin, 44, 765–773.
212.
SuzukiO, AbeM, and HashimotoY. (2015). Sialylation and glycosylation modulate cell adhesion and invasion to extracellular matrix in human malignant lymphoma: Dependency on integrin and the Rho GTPase family. Int J Oncol, 47, 2091–2099.
213.
SvarovskySA, and Joshi L (2014). Cancer glycan biomarkers and their detection–past, present and future. Anal Methods 6, 3918–3936.
214.
TangZ, VargheseRS, BekesovaS, et al. (2010). Identification of N-glycan serum markers associated with hepatocellular carcinoma from mass spectrometry data. J Proteome Res, 9, 104–112.
215.
TeraoY, FujitaH, HoribeS, et al. (2017). Interaction of FAM5C with UDP-glucose: Glycoprotein glucosyltransferase 1 (UGGT1): Implication of N-glycosylation in FAM5C secretion. Biochem Biophys Res Commun, 486, 811–816.
216.
The Gene Ontology Consortium. (2019). The Gene Ontology Resource: 20 years and still GOing strong. Nucleic Acids Res, 47,(D1),D330–D338.
217.
The UniProt Consortium. (2019). UniProt: A worldwide hub of protein knowledge. Nucleic Acids Res, 47, D506–D515.
218.
TheocharisAD, VyniosDH, PapageorgakopoulouN, SkandalisSS, and Theocharis DA (2003). Altered content composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma. Int J Biochem Cell Biol 35, 376–390.
219.
ThomasD, RathinavelAK, and RadhakrishnanP. (2020). Altered glycosylation in cancer: A promising target for biomarkers and therapeutics. Biochim Biophys Acta Rev Cancer, 1875, 188464.
220.
TianY, EstevaFJ, SongJ, and ZhangH. (2012). Altered expression of sialylated glycoproteins in breast cancer using hydrazide chemistry and mass spectrometry. Mol Cell Proteomics 11, M111.011403.
221.
TousiF, BonesJ, IliopoulosO, HancockWS, and HincapieM. (2012). Multidimensional liquid chromatography platform for profiling alterations of clusterin N-glycosylation in the plasma of patients with renal cell carcinoma. J Chromatogr A, 1256, 121–128.
222.
TrouillasJ, DanielL, GuigardM-P, et al. (2003). Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion. J Neurosurg, 98, 1084–1093.
223.
TsaiHY, BoonyapranaiK, SriyamS, et al. (2011). Glycoproteomics analysis to identify a glycoform on haptoglobin associated with lung cancer. Proteomics, 11, 2162–2170.
224.
Tucker-BurdenC, ChappaP, and KrishnamoorthyM. (2012). Lectins identify glycan biomarkers on glioblastoma-derived cancer stem cells. Stem Cells Dev, 21, 2374–2386.
225.
TuranliB, GulfidanG, and ArgaKY. (2017). Transcriptomic-guided drug repositioning supported by a new bioinformatics search tool: GeneXpharma. OMICS,584–591.
226.
TuriákL, SugárS, ÁcsA, et al. (2019). Site-specific N-glycosylation of HeLa cell glycoproteins. Sci Rep, 9, 14822.
227.
TurzanskiJ, GrundyM, ShangS, RussellN, and PallisM. (2005). P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway. Exp Hematol, 33, 62–72.
228.
VajariaBN, PatelKR, BegumR, and PatelPS. (2016). Sialylation: An avenue to target cancer cells. Pathol Oncol Res, 22, 443–447.
229.
ValeroAS, RoldánML, RuizMF, TeijeiroJM, MárquezS, and MariniPE. (2018). Deleted in Malignant Brain Tumor 1 (DMBT1) expression pattern in normal cervix and at different stages of squamous intraepithelial lesions. Open Biomarkers J, 8, 1–8.
230.
VarkiA. (2017). Biological roles of glycans. Glycobiology, 27, 3–49.
231.
ViapianoMS, BiWL, PiepmeierJ, HockfieldS, and MatthewsRT. (2005). Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas. Cancer Res, 65, 6726–6733.
232.
VučkovićF, KrištićJ, GudeljI, et al. (2015). Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome. Arthritis Rheumatol, 67, 2978–2989.
233.
VuckovicF, TheodoratouE, ThaciK, et al. (2016). IgG glycome in colorectal cancer. Clin Cancer Res, 22, 3078–3086.
234.
VuillierF, DumasG, MagnacC, et al. (2005). Lower levels of surface B-cell-receptor expression in chronic lymphocytic leukemia are associated with glycosylation and folding defects of the mu and CD79a chains. Blood, 105, 2933–2940.
235.
WangW, and JiaJT. (1987). Phenotyping of phosphoglucomutase (PGM1) subtypes in Chinese, with special reference to new variant PGM1 China. Med Sci Law, 27, 280–282.
236.
WangB, LiGX, ZhangSG, et al. (2011a). Biglycan expression correlates with aggressiveness and poor prognosis of gastric cancer. Exp Biol Med (Maywood), 236, 1247–1253.
237.
WangJ, SvendsenA, KmiecikJ, et al. (2011b). Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma. PLoS One, 6, e23062.
238.
WangL, MaJ, LiuF, et al. (2007). Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecol Oncol, 105, 695–702.
239.
WangL, SeinoJ, TomotakeH, FunakoshiY, HirayamaH, and SuzukiT. (2015). Co-expression of NEU2 and GBA3 causes a drastic reduction in cytosolic sialyl free N-glycans in human MKN45 stomach cancer cells—Evidence for the physical interaction of NEU2 and GBA3. Biomolecules, 5, 1499–1514.
240.
WangM, LongRE, ComunaleMA, et al. (2009). Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev, 18, 1914–1921.
241.
WangW, and YanY. (2012). Suboptimal health: A new health dimension for translational medicine. Clin Transl Med, 1, 28.
242.
WangW. (2013). Validation and development of N-glycan as biomarker in cancer diagnosis. Curr Pharmacogenomics Person Med, 11, 53–58.
243.
WangY, AduaE, RussellA, et al. (2016a). Glycomics and its application potential in precision medicine. Am Assoc Adv Sci, 354, 36–39.
244.
WangY, KlarićL, YuX, et al. (2016b). The Association Between Glycosylation of Immunoglobulin G and Hypertension: A Multiple Ethnic Cross-Sectional Study. Medicine (Baltimore), 95, e3379.
245.
WangW. (2019). Glycomics research in China: The current state of the art. Omics, 23, 601–602.
246.
WangH, LiX, WangX, LiuD, ZhangX, and CaoW. (2019). Next-Generation (Glycomic) Biomarkers for Cardiometabolic Health: A Community-Based Study of Immunoglobulin GN-Glycans in a Chinese Han Population. Omics, 23, 649–659.
247.
WangS, ItohM, ShiratoriE, OhtakaM, and TohdaS. (2018). NOTCH activation promotes glycosyltransferase expression in human myeloid leukemia cells. Hematol Rep, 10, 7576.
248.
WangH, TianQ, ZhangJ, et al. (2020). Population-based case-control study revealed metabolomic biomarkers of suboptimal health status in Chinese population—potential utility for innovative approach by predictive, preventive, and personalized medicine. EPMA J, 11, 147–160.
249.
WatanabeA, MabuchiT, SatohE, et al. (2006). Expression of syndecans, a heparan sulfate proteoglycan, in malignant gliomas: Participation of nuclear factor-kappaB in upregulation of syndecan-1 expression. J Neurooncol, 77, 25–32.
250.
WeizS, WieczorekM, SchwedlerC, et al. (2016). Acute-phase glycoprotein N-glycome of ovarian cancer patients analyzed by CE-LIF. Electrophoresis, 37, 1461–1467.
251.
WestenfelderC, and BaranowskiRL. (2000). Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int, 58, 647–657.
252.
WikstenJP, LundinJ, NordlingS, et al. (2001). Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer, 95, 1–6.
253.
WiranowskaM, LaddS, SmithSR, and GottschallPE. (2006). CD44 adhesion molecule and neuro-glial proteoglycan NG2 as invasive markers of glioma. Brain Cell Biol, 35, 159–172.
254.
WishartDS, FeunangYD, GuoAC, et al. (2018). DrugBank 5.0: A major update to the Drug Bank database for 2018. Nucleic Acids Res, 46, D1074–D1082.
255.
WongNK, EastonRL, PanicoM, et al. (2003). Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem, 278, 28619–28634.
256.
XiaoZ, LiuQ, MaoF, WuJ, and Lei T (2011). TNF-α-induced VEGF and MMP-9 expression promotes hemorrhagic transformation in pituitary adenomas. Int J Mol Sci 12, 4165–4179.
257.
XuR, CaiMY, LuoRZ, TianX, HanJD, and ChenMK. (2016). The Expression Status and Prognostic Value of Cancer Stem Cell Biomarker CD133 in Cutaneous Squamous Cell Carcinoma. JAMA Dermatol, 152, 305–311.
258.
XuZ, ZhangS, ZhouQ, WangY, and XiaR. (2014). Endocan, a potential prognostic and diagnostic biomarker of acute leukemia. Mol Cell Biochem, 395, 117–12.
259.
YamamotoH, OviedoA, SweeleyC, SaitoT, and MoskalJR. (2001). α2, 6-Sialylation of cell-surface N-glycans inhibits glioma formation in vivo. Cancer Res, 61, 6822–6829.
260.
YamamotoH, SwogerJ, and GreeneS. (2000). β1, 6-N-acetylglucosamine-bearing N-glycans in human gliomas: Implications for a role in regulating invasivity. Cancer Res, 60, 134–142.
261.
YamasakiY, NousoK, MiyaharaK, et al. (2015). Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis. J Gastroenterol Hepatol, 30, 528–534.
262.
YangG, TanZ, LuW, et al. (2015). Quantitative glycome analysis of N-glycan patterns in bladder cancer vs normal bladder cells using an integrated strategy. J Proteome Res, 14, 639–653.
263.
YangWE, HsiehMJ, LinCW, et al. (2017a). Plasma levels of endothelial cell-specific molecule-1 as a potential biomarker of oral cancer progression. Int J Med Sci, 14, 1094–1100.
264.
YangZT, NiWD, LiuXX, XuanYH, and JinY. (2017b). Tenascin-C is a diagnostic marker for cervical cancer and a potential marker for cancer-associated fibroblasts in cervical carcinoma. Int J Clin Exp Pathol, 10, 139–147.
265.
YiJK, ChangJW, HanW, et al. (2009). Autoantibody to tumor antigen, alpha 2-HS glycoprotein: A novel biomarker of breast cancer screening and diagnosis. Cancer Epidemiol Biomarkers Prev, 18, 1357–1364.
266.
YuX, WangY, KristicJ, et al. (2016). Profiling IgG N-glycans as potential biomarker of chronological and biological ages: A community-based study in a Han Chinese population. Medicine (Baltimore), 95, e4112.
267.
YuanP, TemamS, El-NaggarA, et al. (2006). Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer, 107, 563–569.
268.
YueT, GoldsteinIJ, HollingsworthMA, et al. (2009). The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol Cell Proteomics, 8, 1697–1707.
269.
ZengQ, ZhaoRX, ChenJ, et al. (2016). O-linked GlcNAcylation elevated by HPV E6 mediates viral oncogenesis.Proc Natl Acad Sci U S A 113, 9333–9338.
270.
ZhangH, LuoM, LiangX, et al. (2014). Galectin-3 as a marker and potential therapeutic target in breast cancer. PLoS One, 9, e103482.
271.
ZhangQ, HuangR, TangQ, et al. (2018). Leucine-rich alpha-2-glycoprotein-1 is up-regulated in colorectal cancer and is a tumor promoter. Onco Targets Ther, 11, 2745–2752.
272.
ZhangX, DongW, ZhouH, et al. (2015). α-2,8-Sialyltransferase Is Involved in the Development of Multidrug Resistance via PI3K/Akt Pathway in Human Chronic Myeloid Leukemia. IUBMB Life, 67, 77–87.
273.
ZhangY, ZhaoW, ZhaoY, et al. (2020). Comparative glycoproteomic profiling of human body fluid between healthy controls and patients with papillary thyroid carcinoma. J Proteome Res 19,, 7, 2539–2552.
274.
ZhaoL, LiY, SongX, et al. (2016). Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia. Oncotarget, 7, 60074–60086.
275.
ZhaoYP, RuanCP, WangH, et al. (2012). Identification and assessment of new biomarkers for colorectal cancer with serum N-glycan profiling. Cancer, 118, 639–650.
276.
ZhouH, LiY, LiuB, et al. (2016). Downregulation of miR-224 and let-7i contribute to cell survival and chemoresistance in chronic myeloid leukemia cells by regulating ST3GAL IV expression. Gene, 626, 106–118.
277.
ZhouY, ZhouB, PacheL, et al. (2019). Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun, 10, 1–10.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
